GALECTIN THERAPEUTICS INC — Director's Dealing 2020

Sep 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-08-31

Reporting Person: LEWIS JOEL (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-31	Stock option (right to buy)	$2.65	A	250000	Acquired	2030-08-31	Common Stock (250000)	Direct

Footnotes

F1: These options were granted pursuant to Galectin Therapeutics Inc.'s 2019 Omnibus Equity Incentive Plan, and represent a one-time award of securities.

F2: The options vest in twelve equal installments on a quarterly basis, such that the options shall be fully vested three years from the date of grant.